Skip to main
  1. Stocks
  2. NeuroSense Therapeutics Ltd
  3. Forecast
NRSN

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics is compelling fundamentally because PrimeC has repeatedly shown a multi-target mechanism that aligns with the shared biology of ALS, AD, and PD, including reductions in TDP-43, neuroinflammation, and iron dysregulation, while preclinical and biomarker work suggests synergistic activity from ciprofloxacin plus celecoxib rather than simple repurposing. Its clinical package is stronger than a typical early biotech, with Phase 2b PARADIGM in 68 patients showing favorable tolerability, a 65% reduction in death risk (HR=0.35, p=0.004), and median survival of 36.3 months versus 21.4 months, plus supportive Phase 2a and RoAD signals. The upside is further reinforced by a differentiated regulatory path, including FDA-cleared Phase 3 PARAGON and a planned Health Canada NDS in late 4Q26, though limited cash and financing risk remain key valuation overhangs.

Bears say

NeuroSense Therapeutics is facing a weakened investment case because its core thesis depends on PrimeC, yet key milestones have slipped to March 2027 for the Canadian NDS submission and mid-2027 for Phase 3 initiation, increasing execution uncertainty. The company’s financial position is also fragile, with 1H26 EPS of ($2.06) after a 1:20 reverse split and only $0.2 million in cash at the end of 1H26, while continued development is contingent on securing additional funding. In addition, two live Nasdaq deficiencies, including a sub-$1.00 bid price and MVSL below $35 million with a September 29, 2026 cure deadline, raise delisting risk that could further impair financing and clinical progress.

NRSN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

NRSN Analyst Forecast & Price Prediction

Get the latest NRSN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NRSN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 3 analysts, NRSN has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


NRSN Analyst Forecast & Price Prediction

Get the latest NRSN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NRSN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NRSN stock data and trends